Literature DB >> 19604462

Advances in renal bone disease: osteoporosis and chronic kidney disease.

Sara Barnato1, Stuart M Sprague.   

Abstract

Osteoporosis is a common bone disease characterized by low bone density, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. Recent decades have seen major advances in the understanding of the pathophysiology, prevention, and treatment of this disorder. Chronic kidney disease (CKD) affects more than 20 million Americans and is associated with unique metabolic mineral disorders related to low bone density and increased fractures. Because many patients with low bone density may have CKD, and the combination of osteoporosis and CKD may further increase fracture risk with increased morbidity and mortality, appropriate identification is necessary for effective management. The clinical, laboratory, and imaging studies currently used to diagnose osteoporosis in the general population inadequately detect the complex bone and metabolic changes that occur with CKD. This review focuses on the pathophysiology of osteoporosis and CKD and discusses problems with current diagnostic tools and considerations for treatment regimens.

Entities:  

Mesh:

Year:  2009        PMID: 19604462     DOI: 10.1007/s11926-009-0025-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  39 in total

1.  Effect of aluminium load on parathyroid hormone synthesis.

Authors:  C Díaz-Corte; J L Fernández-Martín; S Barreto; C Gómez; T Fernández-Coto; S Braga; J B Cannata
Journal:  Nephrol Dial Transplant       Date:  2001-04       Impact factor: 5.992

2.  Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.

Authors:  Anna L Zisman; Marta Hristova; L Tammy Ho; Stuart M Sprague
Journal:  Am J Nephrol       Date:  2007-01-11       Impact factor: 3.754

3.  Risk factors for hip fracture among patients with end-stage renal disease.

Authors:  C O Stehman-Breen; D J Sherrard; A M Alem; D L Gillen; S R Heckbert; C S Wong; A Ball; N S Weiss
Journal:  Kidney Int       Date:  2000-11       Impact factor: 10.612

4.  Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.

Authors:  Sophie A Jamal; Douglas C Bauer; Kristine E Ensrud; Jane A Cauley; Marc Hochberg; Areef Ishani; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

6.  Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Authors:  Stuart M Sprague; Hanna Abboud; Ping Qiu; Matthew Dauphin; Pinggao Zhang; William Finn
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 8.237

7.  Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Authors:  Jack W Coburn; Hla M Maung; Logan Elangovan; Michael J Germain; Jill S Lindberg; Stuart M Sprague; Mark E Williams; Charles W Bishop
Journal:  Am J Kidney Dis       Date:  2004-05       Impact factor: 8.860

8.  Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.

Authors:  Eduardo Slatopolsky; Mario Cozzolino; Yan Lu; Jane Finch; Andriana Dusso; Marc Staniforth; Yoo Wein; Jee Webster
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

9.  Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.

Authors:  John A Eisman; Roberto Civitelli; Silvano Adami; Edward Czerwinski; Chris Recknor; Richard Prince; Jean-Yves Reginster; Mone Zaidi; Dieter Felsenberg; Claire Hughes; Nicole Mairon; Daiva Masanauskaite; David M Reid; Pierre D Delmas; Robert R Recker
Journal:  J Rheumatol       Date:  2008-02-01       Impact factor: 4.666

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  2 in total

1.  Abdominal Aortic Calcification Is a Significant Poor Prognostic Factor for Clinical Outcomes After Decompressive Laminotomy for Lumbar Spinal Canal Stenosis.

Authors:  Hironobu Sakaura; Daisuke Ikegami; Takahito Fujimori; Tsuyoshi Sugiura; Hajime Owaki; Takeshi Fuji
Journal:  Global Spine J       Date:  2019-02-13

2.  Lifestyle-Related Diseases Affect Surgical Outcomes after Posterior Lumbar Interbody Fusion.

Authors:  Hironobu Sakaura; Toshitada Miwa; Tomoya Yamashita; Yusuke Kuroda; Tetsuo Ohwada
Journal:  Global Spine J       Date:  2015-06-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.